KRAS and malignant colon neoplasm: Therefore, the β-catenin signalling pathway is another potential target for colon cancer treatment.11 Here, we demonstrate that MEK inhibitor sensitivity was driven by the PIK3CA genotype in KRAS mutant colon cancer cells.